Status:
COMPLETED
Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy
Lead Sponsor:
University of Saskatchewan
Conditions:
Malignancy
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
Patients with cancer often require intravenous chemotherapy for long periods of time. Ensuring that these patients have safe and reliable access to the veins for chemotherapy is challenging, and some...
Detailed Description
Hypothesis: The null hypothesis envisions both devices performing similarly in regards to chemotherapy and complications. However, the power injectable population will experience the high flow, large...
Eligibility Criteria
Inclusion
- Consecutive patients breast cancer requiring intravenous chemotherapy, referred from our local Cancer Agency for arm TIVAD, will be included.
Exclusion
- • Those under the age of 16 years;
- Those with uncorrectable blood clotting disorder;
- Pregnant women, as they will not be candidates for chemotherapy;
- Any person with an active infection or immunocompromised state;
- Those on oral or intravenous antibiotics on the day of TIVAD implantation.
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT02282449
Start Date
September 1 2013
End Date
July 1 2016
Last Update
October 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Imaging, Royal University Hospital, 103 Hospital Drive
Saskatoon, Saskatchewan, Canada, S7N 0W8